Identification of high affinity molecules by limited dilution screening
    1.
    发明授权
    Identification of high affinity molecules by limited dilution screening 失效
    通过有限稀释筛选鉴定高亲和力分子

    公开(公告)号:US07754433B2

    公开(公告)日:2010-07-13

    申请号:US10309421

    申请日:2002-12-02

    IPC分类号: G01N33/53

    CPC分类号: G01N33/6854 G01N33/6857

    摘要: Methods are disclosed for determining the relative binding affinities of molecules for their binding partner. One type of molecule is an antibody, which has an antigen binding partner. Antibodies are tested for binding against limited dilutions of antigen. Antibodies that bind to the most dilute antigen concentrations are determined to have a higher relative binding affinity for the antigen than antibodies that only bind to more concentrated antigen preparations.

    摘要翻译: 公开了用于确定其结合配偶体的分子的相对结合亲和力的方法。 一种分子是具有抗原结合配偶体的抗体。 测试抗体与抗原的有限稀释度结合。 确定与最稀释的抗原浓度结合的抗体比仅与结合更浓缩的抗原制剂的抗体相比具有比抗原更高的相对结合亲和力。

    IL-18 binding proteins
    8.
    发明申请
    IL-18 binding proteins 有权
    IL-18结合蛋白

    公开(公告)号:US20050147610A1

    公开(公告)日:2005-07-07

    申请号:US10988360

    申请日:2004-11-12

    摘要: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

    摘要翻译: 本发明包括IL-18结合蛋白,特别是结合人白细胞介素-18(hIL-18)的抗体。 具体地,本发明涉及完全是人抗体的抗体。 优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性,例如在患有hIL-18活性有害的病症的人类受试者中。